PIM1 and myeloproliferative neoplasm: Similar, although weaker, synergistic effects were also observed when Ruxolitinib® (JAKafi) was combined with the same PIM inhibitors (data not shown), indicating that PIM and JAK2 inhibitors form a synergistic combination to inhibit the growth of MPN cell lines.